VivoSeq
Neurology

Restless Legs Syndrome

46

Pipeline Programs↗

4

Active Trials↗

31

Companies Involved↗

Restless Legs Syndrome is a moderately active landscape with 46 programs across 31 companies. The most active players are Vitae Pharmaceuticals Inc., an Allergan affiliate, Astellas, Ligand Pharmaceuticals. 19 therapies are approved with 6 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

58/100

Pipeline Velocity

6/100

Mech. Concentration

12/100

Completion Rate

89/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

V

Vitae Pharmaceuticals Inc., an Allergan affiliate

1 program

Phase 1Astellas logo

Astellas

1 program

Phase 2L

Ligand Pharmaceuticals

1 program

Phase 2Kyowa Kirin Co., Ltd. logo

Kyowa Kirin Co., Ltd.

1 program

Phase 2Teva logo

Teva

1 program

Phase 2P

Parkedale

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Trial Status

89

clinical trials

Completed70 · 79%
Unknown status6 · 7%
Terminated5 · 6%
Withdrawn4 · 4%
Recruiting2 · 2%
Active, not recruiting1 · 1%
Other1 · 1%

Clinical Trials

Trial Activity

89 trials

Using Cannabis to Treat Restless Legs Syndrome
Recruiting·SSunnybrook Health Sciences Centre·N/A·NCT06863740·30 enrolled
Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease
Recruiting·UUniversity of Texas at Austin·Phase 4·NCT03082755·156 enrolled
A Self-Controlled Study on the Treatment of Restless Legs Syndrome in Uremia With Dipyridamole
Active, not recruiting·—·Phase 2/3·NCT07199504·80 enrolled
A Randomized, Placebo-controlled Trial of Prednisone in Refractory Restless Legs Syndrome: a Pilot Study
Not yet recruiting·SScripps Health·Phase 1/2·NCT06631300·50 enrolled
Ropinirole XR (Extended Release) In Patients With Restless Legs Syndrome
Completed·GSK logoGSK·Phase 3·NCT00197080·380 enrolled
Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome)
Completed·GSK logoGSK·Phase 3·NCT00256854·135 enrolled
A Long-Term Extension Trial From Late Phase II of SPM 962 in Patients With Restless Legs Syndrome
Completed·Otsuka logoOtsuka·Phase 2·NCT01562743·185 enrolled
Observational Study of Sifrol® in Patients With Primary Restless Legs Syndrome (RLS)
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·N/A·NCT02248155·2,644 enrolled
Autonomic Function and Cardiovascular Risk in Restless Legs Syndrome
Completed·—·Phase 4·NCT02025608·20 enrolled
Iron Sucrose In The Treatment of Restless Legs Syndrome: Safety of Three Dose Regimens as Evaluated by Clinical Assessments
Completed·AAmerican Regent, Inc.·Phase 2·NCT00895232·21 enrolled
Dose Escalating Study of Rotigotine in Pediatric Subjects With Restless Legs Syndrome
Completed·UCB logoUCB·Phase 2·NCT01495793·42 enrolled
Pramipexole in Out-patients With Idiopathic Restless Legs Syndrome (IRLS)
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 3·NCT00654498·306 enrolled
A Clinical Research Study Evaluating Ropinirole Treatment For Restless Legs Syndrome (RLS)
Completed·GSK logoGSK·Phase 3·NCT00225862·140 enrolled
Rotigotine Restless Legs Syndrome Dose Finding Trial
Completed·UCB logoUCB·Phase 2·NCT00243217·341 enrolled
Restless Legs Syndrome With Iron Deficiency or Anaemia in the 3rd Trimester of Pregnancy
Completed·UUniversity of Zurich·Phase 4·NCT01245777·15 enrolled
Page 1 of 6

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)